共 50 条
The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinsn's Disease Progression and Related Dementia
被引:73
|作者:
Compta, Yaroslau
[1
]
Parkkinen, Laura
[4
]
Kempster, Peter
[2
,3
]
Selikhova, Mariana
[5
]
Lashley, Tammaryn
[5
]
Holton, Janice L.
[5
]
Lees, Andrew J.
[5
]
Revesz, Tamas
[5
]
机构:
[1] Hosp Clin Barcelona, CIBERNED, Parkinson Dis & Movement Disorders Unit, Neurol Serv,IDIBAPS, Barcelona, Spain
[2] Monash Med Ctr, Dept Neurosci, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic 3004, Australia
[4] Univ Oxford, Oxford Parkinsons Dis Ctr, Nuffield Dept Clin Neurosci, Oxford, England
[5] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq Brain Bank Neurol Disorders, London, England
基金:
英国医学研究理事会;
英国惠康基金;
关键词:
Parkinson's disease;
Dementia;
Lewy-type pathology;
Alzheimer-type pathology;
alpha-Synuclein;
Tau;
Amyloid-beta;
Biomarkers;
A-BETA;
ALZHEIMER-PATHOLOGY;
COGNITIVE DECLINE;
LEWY;
DEPOSITION;
RISK;
CSF;
MARKERS;
LOAD;
D O I:
10.1159/000354670
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Background: Dementia is one of the milestones of advanced Parkinson's disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications. Objective: The aim of this study was to review the relative importance of Lewy-related alpha-synuclein and Alzheimer's tau and amyloid-beta (A beta) pathologies in disease progression and dementia in PD. Methods: We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts. Results: Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical A beta burden determining a faster progression to dementia. Conclusion: The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between a-synuclein, tau and A beta and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:154 / 156
页数:3
相关论文